Board
Prof. Dr. Kathrin Adlkofer
In 2017 Prof. Dr. Kathrin Adlkofer founded Cellbox Solutions GmbH, whose operations she leads as COO. In the same year she became a lecturer at the Institut für Entrepreneurship und Business Development of the Universität to Lübeck. Prof. Adlkofer has additionally cofounded companies such as CK Venture GmbH and Vindex GmbH. She is as well member of multiple Scientific communities.
Outside of her business ventures she is also an athletic ace, bringing home multiple Sailing World Championship medals as well as being a 2 times Olympian.
Prof. Dr. Kathrin Adlkofer is member of Bio Deutschland’s board since 2019.
Dr. Jürgen Eck
Dr. Jürgen Eck is the managing director of bio.IMPAKT as well as Co-CEO and CTO of SymbioPharm GmbH and Symbio Group. While also being a cofounder of the BRAIN AG, a paramount company in the industrial biotechnology. Whom he worked for as CTO until 2015 and as CEO until 2019. In 2020 Dr. Eck was invoked to the Bioeconomy committee of the National Government, as well as multiple other committees.
Dr. Jürgen Eck is member of Bio Deutschland’s board since 2019.
Norbert Hentschel, Treasurer
Norbert Hentschel is the managing director Miltenyi Biotec B.V. & Co. KG in Bergisch Gladbach since 2010. Starting originally at the company in 2001 where he oversaw area Controlling, accounting, and information technology. In the years following he started to take over more facets of the company such as the completion of acquisitions, a founding and integration of an Asian sub corporation, and helping the company adjust to massive growth.
Before this, Herr Hentschel received a Masters in economics, leading him to work in finance for E.ON AG, Düsseldorf and next at Arthur Anderson, one of the Big Five of accounting firms.
Norbert Hentschel is member of Bio Deutschland’s board since 2009, and Treasurer since 2019.
Jens Holstein
Jens Holstein is the CFO of BioNTech. Before Jens Holstein came to BioNtech he was the CFO of the publicly traded company, MorphoSys AG, where he worked to create a fully integrated biopharmaceutical company. Before 2011, Jens Holstein had multiple CFO positions and Management duties inside the Frensius SE Group, such as CFO for the Region EME (Europe/ Middle East), and Regional Chief Financial Officer for their sub-corporation Frensius Kabi Asia Pacific Ltd. In Hongkong.
Before these multiple endeavors with Frensius SE Group and its sub- corporations, Mr. Holstein was active for multiple years in the consulting industry in M&A with positions in Frankfurt and London.
Outside of being member of Bio Deutschland’s board, he is also a Non-executive member of the Board of Directors for the genomic diagnostics company Veracyte Inc.
Dr. Klaus Maleck
Dr. Klaus Maleck is the CFO of the ITM Group, a private radiopharmaceutical Bio-tech company founded in 2004, while also being an operating partner of Archimed SAS.
Before these current endeavors, Dr. Maleck was CEO of TETEC AG, a fully integrated development and production company for regenerative medicine, within the Aesculap/B Braun-Group.
Roland Sackers
Roland Sackers is CFO and Managing Director of the Qiagen N.V. Outside of the financial aspects of the company, Mr. Sackers also is responsible for the IT, IR, PR, and purchases of the company.
During the early 2020’s as Covid became a major concern Mr. Sackers was in charge of creation communication lines to international regulatory agencies and governments to further the companies infection risk reducing programs and tools.
Before stepping into Qiagen in 1999, and becoming CFO in 2004, Mr. Sackers worked as Arthur Anderson, one of the Big Five of accounting firms.
Roland Sackers is member of Bio Deutschland’s board since 2009.
Oliver Schacht Ph.D., Chairman of the Board
Oliver Schacht is CEO of OpGen Inc. In Rockville, MD, USA since April of 2020, and Managing Director of the Curetis GmbH in Holzgerlingen since 2011. He was cofounder of the Epigenomics AG in Berlin and CEO of its sub- corporation in the US.
He is a well known expert in the Diagnostics Industry, having great experience in the development and substantiating of Strategies, Financing Measures, Finance, M&A Transfers, and Cooperation talks. His work now specifies mainly within the pharmaceutical industry due to his past activities in the reorganization and growth strategies of many start ups and established companies in the Biotech Industry.
Oliver Schacht Ph.D. is member of Bio Deutschland’s board since 2013, and Chairman of the Board since 2019.
Dr. Kirsten Tief-Küry
Dr. Kirsten Tief-Küry has for the last 16 years been active at Thermo Fisher in different leading roles. Currently she is Chairwoman of the Supervisory Board of Thermo Fisher Scientific GmbH and Managing Director of Life Technology GmbH. While also managing the Diversity and Inclusion Women Chapter Life Technologies in Europe. Dr. Tief-Küry is active worldwide with experience in Biotech, Biopharma, and Medicine.
With more specific knowledge in Molecular Diagnostics, Cancer Genomics, infectious diseases, and medical equipment. Due to this knowledge, she is involved in Teams of strategic planning, Business Development, and Portfolio Marketing throughout the EMEA- Region (Asia and South America).
Dr. Tief-Küry has through her leading role been able to hold contact with political organizations within Europe, as well as the WHO, specifically providing newly industrialized countries financial and medical knowledge to help expand their Biotechnological industries.
Dr. Sylvia Wojczewski
Dr. Sylvia Wojczewski is CEO and co-owner of the BioSpring GmbH. A leading company in the development and analysis of high-quality Nucleic Acid for therapeutical and diagnostic uses in both research and development as well as clinical studies and commercially available medicines.
Dr. Sylvia Wojczewski is member of Bio Deutschland’s board since 2013.
Dr. Holger Zimmermann
Dr. Holger Zimmermann has since 2023 been the Chief Research and Development Officer of AiCuris, but has since 2015 been the CEO of the company. Before this, Dr. Zimmermann was Managing Director, deputy CEO, and CSO for the six years prior. He was in charge of the successful HCMV-Portfolio which was licensed out to Merck & Co.
Before stepping over to AiCuris, Dr. Zimmermann was Lab and Project manager for Virology at Bayer Healthcare.
Dr. Holger Zimmermann is member of Bio Deutschland’s board since 2015.